Main Content

“2020health is an important and thoughtful contributor to the health debate”

Dr Sarah Wollaston MP, Chairman, Health Select Committee


Intellectual Property and Research with Penny Mordaunt MP

May 10. till May 10.

2020health Expert Roundtable on Intellectual Property and Research with Penny Mordaunt MP

2020health roundtable discussion breakfast event on the recent development in Intellectual Property rights and research.

May 10, 20112011-05-10T08:30:00 - May 10, 2011 2011-05-10T10:00:00
8:30 AM 2011-05-10T08:30:00 - 10:00 AM 2011-05-10T10:00:00
House of Commons, Westminster, London


1)Penny Mordaunt MP (unable to attend)        
2) Chris Brinsmead, Life Science Business advisor, UKTI Life Sciences Marketing Board
3) Dr David Chilvers (unable to attend), CEO, NHS Innovations London
4) Barbara Arzymanow, Director, True Research Limited
5) Becky Purvis, Head of Policy, AMRC
6) Steve Bates, CEO, Genzyme
7) Jason Rutt, UK Patent Department Head, Pfizer UK
8) Iain Connor, Partner, Pinsent Masons LLP
9) Gail Beer, Consultant Director,
10)Julia Manning, Chief Executive,
11) Dr Eleanor Winpenny, Researcher,

Key Points

Global companies make global decisions – the government doesn’t always understand this – it needs to look at the global landscape when considering policy to attract business to the UK.

The OLS wants to implement the whole of the OLS Blueprint, to make the UK more attractive as a whole to investors. Faster NICE approvals, for example through allowing these to be done at the same time as Marketing Authorisation. All top US hospitals have research as a top priority as they know that this leads to better patient care.

Should a requirement for more research be built into the health bill?
Could tariffs be built into monitor to incentivise research?
Patients should be given more opportunities to be involved in research.
Should the NHS be called the NHRS – the National Health and Research Service, to make clear how much research is done?

One way to encourage good communication is using a speech. An annual ‘State of the Nation’ speech on life sciences would pull everyone together, providing a document that can then be used for leadership and direction.

The government should use the pause in the progression of the Health Bill to reflect on whether they really want to proceed with value-based pricing within this parliament.

With no Government funding any more for Health IP or early stage product development that we will not be able to:

- Find, generate and protect UK innovations in health

- Get industry or investors to take up and develop UK research/inventions without strong IP

- Continue with product development on life saving technologies (e.g. stem cell transplants, aortic repairs, early detection/prevention heart attacks, improved Parkinson’s treatment, etc.)